UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________________________________________________________

FORM 6-K

______________________________________________________________________

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2020

______________________________________________________________________

Commission File Number: 001-38067

______________________________________________________________________

Verona Pharma plc

(Translation of registrant's name into English)

______________________________________________________________________

3 More London Riverside

London SE1 2RE UK

+44 203 283 4200

(Address of principal executive office)

______________________________________________________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On November 11, 2020, Verona Pharma plc posted or made available to its shareholders on its website certain material related to the general meeting of shareholders to be held on December 18, 2020 (the “Shareholder Materials”).

The Shareholder Materials are furnished herewith as Exhibits 1 through 3 to this Report on Form 6-K.

EXHIBIT INDEX

Exhibit No.	Description
1	Notice of General Meeting of Verona Pharma plc.
2	Form of Proxy.
3	Proposed Articles of Association, marked to show changes.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	VERONA PHARMA PLC
Date: November 12, 2020		By:	/s/ David Zaccardelli
			Name:	David Zaccardelli, Pharm. D.
			Title:	President and Chief Executive Officer